

Akshay K Gupta, Ajay Gupta, Ajay K

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/386593/publications.pdf>

Version: 2024-02-01

52
papers

2,422
citations

394421

19
h-index

233421

45
g-index

53
all docs

53
docs citations

53
times ranked

4058
citing authors

#	ARTICLE	IF	CITATIONS
1	Inorganic nitrate attenuates cardiac dysfunction: roles for xanthine oxidoreductase and nitric oxide. <i>British Journal of Pharmacology</i> , 2022, 179, 4757-4777.	5.4	5
2	Malignant Hypertension: Current Perspectives and Challenges. <i>Journal of the American Heart Association</i> , 2022, 11, e023397.	3.7	14
3	Blood Pressureâ€“Lowering Effects of Omegaâ€“3 Polyunsaturated Fatty Acids: Are These the Missing Link to Explain the Relationship Between Omegaâ€“3 Polyunsaturated Fatty Acids and Cardiovascular Disease?. <i>Journal of the American Heart Association</i> , 2022, 11, .	3.7	0
4	Role of plasma extracellular vesicles in prediction of cardiovascular risk and alterations in response to statin therapy in hypertensive patients. <i>Journal of Hypertension</i> , 2022, 40, 1522-1529.	0.5	4
5	COVID-19: Causes of anxiety and wellbeing support needs of healthcare professionals in the UK: A cross-sectional survey. <i>Clinical Medicine</i> , 2021, 21, 66-72.	1.9	41
6	Early and Mid-Term Implications of the COVID-19 Pandemic on the Physical, Behavioral and Mental Health of Healthcare Professionals: The CoPE-HCP Study Protocol. <i>Frontiers in Psychology</i> , 2021, 12, 616280.	2.1	7
7	COMPARING THE DISCRIMINATIVE ABILITY OF DIFFERENT ELECTROGRAPHIC CRITERIA FOR LEFT VENTRICULAR HYPERTROPHY IN PREDICTING CARDIOVASCULAR EVENTS IN HYPERTENSIVE PATIENTS. <i>Journal of Hypertension</i> , 2021, 39, e165-e166.	0.5	0
8	LONG TERM BENEFITS OF BLOOD PRESSURE TREATMENT ON THE INCIDENCE OF ATRIAL FIBRILLATION, HEART FAILURE AND CARDIOVASCULAR MORBIDITY AND MORTALITY: 20-YEARS FOLLOW-UP OF ASCOT-LEGACY. <i>Journal of Hypertension</i> , 2021, 39, e8.	0.5	4
9	INFLUENCE OF AGE, SEX AND AN OCCURRENCE OF CARDIOVASCULAR EVENT ON SEASONAL VARIATIONS IN BLOOD PRESSURES IN HYPERTENSIVE PATIENTS: INSIGHTS FROM THE ASCOT COHORT. <i>Journal of Hypertension</i> , 2021, 39, e145-e146.	0.5	0
10	Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis. <i>Lancet Oncology</i> , The, 2021, 22, 558-570.	10.7	56
11	THE DEVELOPMENT OF RESISTANT HYPERTENSION INDEPENDENT OF THE PRECEDING PERIOD OF THE BLOOD PRESSURE CONTROL IS ASSOCIATED WITH THE INCREASED RISK OF CARDIOVASCULAR EVENTS AND DEATH. <i>Journal of Hypertension</i> , 2021, 39, e358.	0.5	0
12	THE RELATIONSHIP BETWEEN BP-CONTROL, BP -VARIABILITY AND ANTIHYPERTENSIVE TREATMENT WITH THE LONG-TERM RISK OF CARDIOVASCULAR EVENT: LESSONS FROM THE ASCOT-LEGACY 20 YEAR FOLLOW-UP. <i>Journal of Hypertension</i> , 2021, 39, e148.	0.5	2
13	<i>JAHA</i> Spotlight on Air Pollution and Cardiovascular Disease: A Call for Urgent Action. <i>Journal of the American Heart Association</i> , 2021, 10, e022209.	3.7	5
14	COVID-19 and the Digitalisation of Cardiovascular Training and Educationâ€“A Review of Guiding Themes for Equitable and Effective Post-graduate Telelearning. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 666119.	2.4	6
15	Long-Term Incidence of Stroke and Dementia in ASCOT. <i>Stroke</i> , 2021, 52, 3088-3096.	2.0	7
16	Equity, Diversity, and Inclusiveness in Cardiovascular Medicine and Health Care. <i>Journal of the American Heart Association</i> , 2020, 9, e019137.	3.7	3
17	Diversity, Equity, and Inclusiveness in Medicine and Cardiology: Next Steps for JAHA. <i>Journal of the American Heart Association</i> , 2020, 9, e019307.	3.7	1
18	Solar UV Radiation: A Potential Modifiable Risk Factor for Hypertension. <i>Journal of the American Heart Association</i> , 2020, 9, e015627.	3.7	4

#	ARTICLE	IF	CITATIONS
19	Current Perspectives on Coronavirus Disease 2019 and Cardiovascular Disease: A White Paper by the <i>JAHA</i> Editors. <i>Journal of the American Heart Association</i> , 2020, 9, e017013.	3.7	52
20	Impact of the New ACC/AHA and ESC/ESH Hypertension Guidelines in the UK. <i>European Heart Journal</i> , 2019, 40, 2472-2475.	2.2	2
21	Over 1000 genetic loci influencing blood pressure with multiple systems and tissues implicated. <i>Human Molecular Genetics</i> , 2019, 28, R151-R161.	2.9	39
22	Efficacy and Safety of Incremental Dosing of a New Single-Pill Formulation of Perindopril and Amlodipine in the Management of Hypertension. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 313-323.	2.2	9
23	Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500,000 patients with Type 2 diabetes mellitus. <i>European Heart Journal</i> , 2019, 40, 2899-2906.	2.2	59
24	Antral resection versus antral preservation during laparoscopic sleeve gastrectomy for severe obesity: Systematic review and meta-analysis. <i>Surgery for Obesity and Related Diseases</i> , 2018, 14, 857-864.	1.2	37
25	A17615 Baseline predictors of all-cause- and cardiovascular- mortality amongst 8580 hypertensive patients followed up for 16 years in the ASCOT legacy study. <i>Journal of Hypertension</i> , 2018, 36, e251.	0.5	0
26	Hypertensive Disorders in Pregnancy and the Risk of Cardiovascular Disease: A Need for Postpartum Strategies for the Primary Prevention. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	1
27	Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. <i>Lancet, The</i> , 2018, 392, 1127-1137.	13.7	87
28	Attenuation of Splanchnic Autotransfusion Following Noninvasive Ultrasound Renal Denervation: A Novel Marker of Procedural Success. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	13
29	Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trialâ€™Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. <i>Lancet, The</i> , 2017, 389, 2473-2481.	13.7	279
30	Concerns related to the nocebo effect â€™ Authors' reply. <i>Lancet, The</i> , 2017, 390, 1832.	13.7	2
31	Implementation of depression screening in antenatal clinics through tablet computers: results of a feasibility study. <i>BMC Medical Informatics and Decision Making</i> , 2017, 17, 59.	3.0	13
32	Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients. <i>Clinical Research in Cardiology</i> , 2017, 106, 58-68.	3.3	23
33	LBOS 01-04 THE TRUE INCIDENCE OF STATIN -RELATED ADVERSE EVENTS IN HYPERTENSIVE PATIENTS REVEALED BY COMPARISON OF BLINDED AND UN-BLINDED USE OF STATIN IN THE ANGLO-SCANDINAVIAN CARDIAC OUTCOMES TRIAL (ASCOT). <i>Journal of Hypertension</i> , 2016, 34, e547-e548.	0.5	2
34	Tablet computers for implementing NICE antenatal mental health guidelines: protocol of a feasibility study. <i>BMJ Open</i> , 2016, 6, e009930.	1.9	6
35	ASCORE: an up-to-date cardiovascular risk score for hypertensive patients reflecting contemporary clinical practice developed using the (ASCOT-BPLA) trial data. <i>Journal of Human Hypertension</i> , 2013, 27, 492-496.	2.2	14
36	Pollutants Source Control and Health Effects. <i>Journal of Environmental and Public Health</i> , 2013, 2013, 1-2.	0.9	4

#	ARTICLE	IF	CITATIONS
37	Childhood Obesity: Today and Tomorrow's Health Challenge. <i>Journal of Obesity</i> , 2013, 2013, 1-2.	2.7	3
38	Is plasma renin activity a biomarker for the prediction of renal and cardiovascular outcomes in treated hypertensive patients? Observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). <i>European Heart Journal</i> , 2012, 33, 2970-2979.	2.2	14
39	The Efficacy and Tolerability of "Polypills": Meta-Analysis of Randomised Controlled Trials. <i>PLoS ONE</i> , 2012, 7, e52145.	2.5	74
40	Role of phytosterols in lipid-lowering: current perspectives. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2011, 104, 301-308.	0.5	85
41	The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the UK. <i>European Heart Journal</i> , 2011, 32, 2525-2532.	2.2	110
42	Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. <i>Lancet Oncology</i> , The, 2011, 12, 65-82.	10.7	332
43	Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT). <i>Journal of Hypertension</i> , 2011, 29, 2004-2013.	0.5	147
44	Metabolic syndrome, impaired fasting glucose and obesity, as predictors of incident diabetes in 14,120 hypertensive patients of ASCOT-BPLA: comparison of their relative predictability using a novel approach. <i>Diabetic Medicine</i> , 2011, 28, 941-947.	2.3	20
45	The efficacy and cost-effectiveness of statins in low-risk patients. <i>Cmaj</i> , 2011, 183, 1821-1823.	2.0	2
46	Metabolic Syndrome, Independent of Its Components, Is a Risk Factor for Stroke and Death But Not for Coronary Heart Disease Among Hypertensive Patients in the ASCOT-BPLA. <i>Diabetes Care</i> , 2010, 33, 1647-1651.	8.6	37
47	Ethnic Differences in Blood Pressure Response to First and Second-Line Antihypertensive Therapies in Patients Randomized in the ASCOT Trial. <i>American Journal of Hypertension</i> , 2010, 23, 1023-1030.	2.0	72
48	The Concept of the Metabolic Syndrome. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1355-1356.	2.8	3
49	Compliance, Safety, and Effectiveness of Fixed-Dose Combinations of Antihypertensive Agents. <i>Hypertension</i> , 2010, 55, 399-407.	2.7	579
50	Determinants of New-Onset Diabetes Among 19,257 Hypertensive Patients Randomized in the Anglo-Scandinavian Cardiac Outcomes Trial's Blood Pressure Lowering Arm and the Relative Influence of Antihypertensive Medication. <i>Diabetes Care</i> , 2008, 31, 982-988.	8.6	142
51	Antihypertensive-Associated Incident Diabetes: Controversy Persists. <i>Archives of Internal Medicine</i> , 2007, 167, 1433.	3.8	1
52	Improving the Prognosis in Patients With Diabetes: What Will ADVANCE Tell Us?. <i>American Journal of Hypertension</i> , 2007, 20, S19-S22.	2.0	0